Document/ExhibitDescriptionPagesSize 1: 10-Q Form 10-Q Q3 2020 HTML 934K
2: EX-31.1 EX-31.1 Q3 2020 CEO Certification HTML 21K
3: EX-31.2 EX-31.2 Q3 2020 CFO Certification HTML 21K
4: EX-32 EX-32 Q3 2020 CEO and CFO Certification HTML 18K
11: R1 Document and Entity Information Document HTML 69K
12: R2 Interim Consolidated Statements of Operations HTML 89K
(Unaudited)
13: R3 Interim Consolidated Balance Sheets (Unaudited) HTML 110K
14: R4 Balance Sheet Parentheticals (Parentheticals) HTML 33K
15: R5 Interim Consolidated Statements of Shareholders' HTML 84K
Equity and Comprehensive Income (Unaudited)
16: R6 Interim Consolidated Statements of Cash Flows HTML 94K
(Unaudited)
17: R7 Other Comprehensive Income HTML 98K
18: R8 Other Comprehensive Income HTML 57K
19: R9 Other Comprehensive Income HTML 50K
20: R10 Other Comprehensive Income Details 2 HTML 44K
21: R11 Other Comprehensive Income Details 3 HTML 31K
22: R12 Basis of Presentation HTML 23K
23: R13 Summary of Significant Accounting Policies HTML 67K
24: R14 Revenue from Contracts with Customers (Notes) HTML 127K
25: R15 Financial Instruments (Notes) HTML 25K
26: R16 Fair Value Measurements HTML 40K
27: R17 Income Taxes HTML 21K
28: R18 Debt HTML 46K
29: R19 Share Repurchase Program and Treasury Stock HTML 20K
30: R20 Earnings Per Common Share HTML 24K
31: R21 Net Periodic Benefit Cost HTML 83K
32: R22 Restructuring Charges HTML 24K
33: R23 Other Charges (Income), Net HTML 19K
34: R24 Contingencies HTML 20K
35: R25 Summary of Significant Accounting Policies HTML 93K
(Policies)
36: R26 Summary of Significant Accounting Policies HTML 51K
(Tables)
37: R27 Revenue from Contracts with Customers (Tables) HTML 124K
38: R28 Fair Value Measurements (Tables) HTML 35K
39: R29 Debt (Tables) HTML 18K
40: R30 Net Periodic Benefit Cost (Tables) HTML 79K
41: R31 Restructuring Charges (Tables) HTML 24K
42: R32 Segment Reporting (Tables) HTML 122K
43: R33 Summary of Significant Accounting Policies HTML 25K
(Details)
44: R34 Summary of Significant Accounting Policies HTML 41K
(Details 1)
45: R35 Summary of Significant Accounting Policies HTML 43K
(Details Textuals)
46: R36 Revenue from Contracts with Customers (Details) HTML 87K
47: R37 Revenue from Contracts with Customers 2 (Details) HTML 28K
48: R38 Financial Instruments (Details) HTML 54K
49: R39 Fair Value Measurements (Details) HTML 43K
50: R40 Income Taxes (Details) HTML 19K
51: R41 Debt (Details) HTML 145K
52: R42 Share Repurchase Program and Treasury Stock HTML 34K
(Details)
53: R43 Earnings Per Common Share (Details) HTML 25K
54: R44 Net Periodic Benefit Cost (Details) HTML 52K
55: R45 Restructuring Charges (Details) HTML 28K
56: R46 Restructuring Charges Restructuring Charges HTML 20K
(Textuals) (Details)
57: R47 Other Charges , Net Other Charges, Net (Details) HTML 19K
58: R48 Segment Reporting (Details) HTML 60K
59: R49 Segment Reporting (Details 1) HTML 34K
60: R50 Segment Reporting (Details Textuals) HTML 32K
62: XML IDEA XML File -- Filing Summary XML 111K
10: XML XBRL Instance -- mtd-20200930_htm XML 2.40M
61: EXCEL IDEA Workbook of Financial Reports XLSX 82K
6: EX-101.CAL XBRL Calculations -- mtd-20200930_cal XML 144K
7: EX-101.DEF XBRL Definitions -- mtd-20200930_def XML 558K
8: EX-101.LAB XBRL Labels -- mtd-20200930_lab XML 1.19M
9: EX-101.PRE XBRL Presentations -- mtd-20200930_pre XML 691K
5: EX-101.SCH XBRL Schema -- mtd-20200930 XSD 123K
63: JSON XBRL Instance as JSON Data -- MetaLinks 311± 431K
64: ZIP XBRL Zipped Folder -- 0001037646-20-000030-xbrl Zip 258K
i☒ QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED iSEPTEMBER 30, 2020, OR
i☐ TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________ TO ________________
(Former
name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
iCommon
Stock, $0.01 par value
iMTD
iNew York Stock Exchange
Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. iYes☒ No☐
Indicate by checkmark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). iYes☒ No ☐
Indicate
by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,”“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): iLarge accelerated filer.☒Accelerated filer☐ Non-accelerated filer ☐ Smaller reporting company i☐ Emerging growth companyi☐
If an emerging growth company, indicate by check mark if the registrant has elected not use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yesi☐ No☒
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
1.iBASIS
OF PRESENTATION
Mettler-Toledo International Inc. ("Mettler-Toledo" or the "Company") is a leading global supplier of precision instruments and services. The Company manufactures weighing instruments for use in laboratory, industrial, packaging, logistics and food retailing applications. The Company also manufactures several related analytical instruments and provides automated chemistry solutions used in drug and chemical compound discovery and development. In addition, the Company manufactures metal detection and other end-of-line inspection systems used in production and packaging and provides solutions for use in certain process analytics applications.
The Company's primary manufacturing facilities are located in China, Germany, Switzerland, the United Kingdom and the United States. The Company's principal executive offices are located in Columbus, Ohio and Greifensee, Switzerland.
The accompanying interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all entities in which the Company has control, which are its wholly-owned subsidiaries. The interim consolidated financial statements have been prepared
without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
The accompanying interim consolidated financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results of the interim periods presented. Operating results for the three and nine months ended September 30,
2020 are not necessarily indicative of the results to be expected for the full year ending December 31, 2020.
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors. A discussion of the Company’s critical accounting policies is included in Management’s Discussion and Analysis of Financial Condition and Results of Operations and the
Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
All intercompany transactions and balances have been eliminated.
2.iSUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
i
Trade Accounts Receivable
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for expected credit losses represents the Company’s best estimate based on historical information, current information, and reasonable and supportable forecasts of future events and circumstances.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
i
Inventories
Inventories are valued at the lower of cost or net realizable value. Cost, which includes direct materials, labor and overhead, is generally determined using the first in, first out (FIFO) method. The estimated net realizable value is based on
assumptions for future demand and related pricing. Adjustments to the cost basis of the Company’s inventory are made for excess and obsolete items based on usage, orders and technological obsolescence. If actual market conditions are less favorable than those projected by management, reductions in the value of inventory may be required.
Goodwill, representing the excess of purchase price over the net asset value of companies acquired, and indefinite-lived intangible assets are not amortized, but are reviewed for impairment annually in the fourth quarter, or more frequently if events or changes in circumstances indicate that an asset might be impaired. The annual evaluation for goodwill and indefinite-lived intangible assets are generally based on an assessment of qualitative and quantitative factors to determine whether it is more likely than not that the fair value of the asset is less than its carrying amount.
Other intangible assets include indefinite-lived assets and assets subject to amortization. Where applicable, amortization is charged on a straight-line basis over the expected period of benefit. The straight-line method of amortization reflects an appropriate allocation of
the cost of the intangible assets to earnings in proportion to the amount of economic benefits obtained by the Company in each reporting period. The Company assesses the initial acquisition of intangible assets in accordance with the provisions of ASC 805 "Business Combinations" and the continued accounting for previously recognized intangible assets and goodwill in accordance with the provisions of ASC 350 "Intangible - Goodwill and Other" and ASC 360 "Property, Plant and Equipment".
i
Other
intangible assets consisted of the following:
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
The Company recognized amortization expense associated with the above intangible assets of $i4.0
million and $i3.8 million for the three months ended September 30, 2020 and 2019, respectively and $i11.8
million and $i11.3 million for the nine months ended September 30, 2020 and 2019, respectively. The annual aggregate amortization expense based on the current balance of other intangible assets is estimated at $i15.8
million for 2020, $i14.7 million for 2021, $i13.2
million for 2022, $i14.0 million for 2023, $i12.7
million for 2024 and $i11.8 million for 2025. Purchased intangible amortization was $i3.8
million, $i2.8 million after tax, and $i3.7 million, $i2.8
million after tax, for the three months ended September 30, 2020 and 2019, respectively and $i11.2 million, $i8.5
million after tax, and $i10.6 million, $i8.0 million after tax, for the nine months ended September 30,
2020 and 2019, respectively.
In addition to the above amortization, the Company recorded amortization expense associated with capitalized software of $i10.1 million and $i8.4
million for the three months ended September 30, 2020 and 2019, respectively and $i30.0 million and $i25.4
million for the nine months ended September 30, 2020 and 2019, respectively.
i
Revenue Recognition
Product revenue is recognized from contracts with customers when a customer has obtained control of a product. The Company considers control to have transferred based upon shipping
terms. To the extent the Company’s arrangements have a separate performance obligation, revenue related to any post-shipment performance obligation is deferred until completed. Shipping and handling costs charged to customers are included in total net sales and the associated expense is a component of cost of sales. Certain products are also sold through indirect distribution channels whereby the distributor assumes any further obligations to the end customer. Revenue is recognized on these distributor arrangements upon transfer of control to the distributor. Contracts do not contain variable pricing arrangements that are retrospective, except for rebate programs. Rebates are estimated based on expected sales volumes and offset against revenue at the time such revenue is recognized. The
Company generally maintains the right to accept or reject a product return in its terms and conditions and also maintains appropriate accruals for outstanding credits. The related provisions for estimated returns and rebates are immaterial to the consolidated financial statements.
Certain of the Company’s product arrangements include separate performance obligations, primarily related to installation. Such performance obligations are accounted for separately when the deliverables have stand-alone value and the satisfaction of the undelivered performance obligations is probable and within the Company's control. The allocation of revenue between the performance obligations is based on the observable stand-alone selling prices at the time of the sale
in accordance with a number of factors including service technician billing rates, time to install, and geographic location.
Software is generally not considered a distinct performance obligation with the exception of a few small software applications. The Company generally does not sell software products without the related hardware instrument as the software is embedded in the product. The Company’s products typically require no significant production, modification, or customization of the hardware or software that is essential to the functionality of the products.
Service revenue not under contract is recognized
upon the completion of the service performed. Revenue from spare parts sold on a stand-alone basis is recognized when control is transferred to the customer, which is generally at the time of shipment or delivery. Revenue from service contracts is recognized ratably over the contract period using a time-based method. These contracts represent an obligation to perform repair and other services including regulatory compliance qualification, calibration, certification, and preventative maintenance on a customer’s pre-defined equipment over the contract period.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
i
Leases
The
Company considers an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. The Company has operating leases, but does not have financing leases.
Operating lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the lease payments over the lease term. Lease payments include both lease and non-lease components for items or activities that transfer a good and service. Vehicle lease and non-lease components are separately accounted for based on standalone value. Real estate lease and non-lease components are accounted for
as a single component. Operating lease right-of-use assets include initial direct costs, advanced lease payments and lease incentives.
The lease term reflects the noncancellable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. The Company generally uses its incremental borrowing rate at the lease commencement date in determining the present value of lease payments as the information necessary to determine the rate implicit in the lease is not readily available. The incremental borrowing rate reflects similar terms by geographic location to the underlying leases. The Company's lease agreements do not contain any material residual value
guarantees or material restrictive covenants.
Lease expense for operating leases is recognized on a straight-line basis over the lease term. Variable lease payments consist of non-lease services related to the lease. Variable lease payments are excluded from the right-of-use asset and lease liabilities and are expensed as incurred. Short-term leases are less than one year without purchase or renewal options that are reasonably certain to be exercised and are recognized on a straight-line basis over the lease term. The right-of-use asset is tested for impairment in accordance with ASC 360.
i
Warranty
The
Company generally offers one-year warranties on most of its products. Product warranties are recorded at the time revenue is recognized. While the Company engages in extensive product quality programs and processes, its warranty obligations are affected by product failure rates, material usage and service costs incurred in correcting a product failure.
iEmployee Termination Benefits
In
situations where contractual termination benefits exist, the Company records accruals for employee termination benefits when it is probable that a liability has been incurred and the amount of the liability is reasonably estimable. All other employee termination arrangements are recognized and measured at their fair value at the communication date unless the employee is required to render additional service after the legal notification period, in which case the liability is recognized ratably over the future service period.
i
Share-Based
Compensation
The Company recognizes share-based compensation expense within selling, general and administrative in the consolidated statements of operations and other comprehensive income with a corresponding offset to additional paid-in capital in the consolidated balance sheet. The Company recorded $i4.4 million and
$i13.2 million of share-based compensation expense for the three and nine months ended September 30, 2020, respectively, compared to $i4.5
million and $i13.3 million for the corresponding periods in 2019.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
i
Research and Development
Research and development costs primarily consist of salaries, consulting and other costs. The Company expenses these costs as incurred.
i
Business
Combinations and Asset Acquisitions
The Company accounts for business acquisitions under the accounting standards for business combinations. The results of each acquisition are included in the Company's consolidated results as of the acquisition date. The purchase price of an acquisition is allocated to tangible and intangible assets and assumed liabilities based on their estimated fair values and any consideration in excess of the net assets acquired is recognized as goodwill. Acquisition transaction costs are expensed when incurred.
In circumstances where an acquisition involves a contingent consideration arrangement, the
Company recognizes a liability equal to the fair value of the expected contingent payments as of the acquisition date. Subsequent changes in the fair value of the contingent consideration are recorded to other charges (income), net.
i
Recent Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13: Financial Instruments - Credit Losses. The ASU requires the allowance for doubtful accounts to be estimated based on an incurred loss model, which considers
historical and forecasted conditions. The guidance became effective for the CompanyJanuary 1, 2020 on a prospective basis and did not have an impact on the consolidated financial statements.
In August 2018, the FASB issued ASU 2018-14: Compensation - Retirement Benefit which amends the current disclosure requirements for defined benefit pension plans and other post-retirement plans. The change in the disclosures will be applied retrospectively and becomes effective for fiscal years ending after December 15, 2020 with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the consolidated financial statements.
In
August 2018, the FASB issued ASU 2018-15: Internal-Use Software which clarifies the accounting for implementation costs associated with cloud-computing internal-use software arrangements. The implementation costs should be capitalized and expensed over the service term, including options to extend, and recognized in selling, general, and administrative in the statement of operations. The guidance became effective January 1, 2020 and is applied on a prospective basis. The adoption of this guidance did not have a material impact on the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12: Income Taxes which removes certain exceptions to the general principles of ASC 740 related to intraperiod tax allocation exceptions, deferred tax liabilities related to outside basis differences, and year-to-date losses in interim
periods. In addition, the ASU amends the interim guidance to clarify that all tax effects, both deferred and current, related to enactments of tax laws or rate changes should be accounted for in the interim period that includes the enactment date. The change is applied prospectively and becomes effective for fiscal years beginning after December 15, 2020 with early adoption permitted. The Company is currently evaluating the impact of this guidance on the consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04: Reference Rate Reform which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and
other transactions affected by discontinuance of LIBOR or another referenced rate. The guidance may be applied to any applicable contract entered into before December 31, 2022. The Company is currently evaluating the impact of this guidance on the consolidated financial statements.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
3.iREVENUE
The Company disaggregates revenue from contracts
with customers by product, service, timing of revenue recognition and geography. A summary of revenue by the Company’s reportable segments for the three and nine months ended September 30, 2020 and 2019 follows:
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
A summary of revenue by major geographic destination for the three and nine months ended September 30 follows:
Three
Months Ended
Nine Months Ended
2020
2019
2020
2019
Americas
$
i304,963
$
i298,304
$
i840,087
$
i849,282
Europe
i232,133
i212,736
i621,126
i629,600
Asia
/ Rest of World
i270,261
i242,826
i685,979
i685,802
Total
$
i807,357
$
i753,866
$
i2,147,192
$
i2,164,684
The
Company's global revenue mix by product category is comprised of laboratory (i54% of sales), industrial (i40% of sales) and retail
(i6% of sales). The Company's product revenue by reportable segment is proportionately similar to the Company's global mix except the Company's Swiss Operations is largely comprised of laboratory products while the
Company's Chinese Operations has a slightly higher percentage of industrial products. A summary of the Company’s revenue by product category for the three and nine months ended September 30 is as follows:
Three Months Ended
Nine
Months Ended
2020
2019
2020
2019
Laboratory
$
i430,516
$
i388,441
$
i1,147,078
$
i1,127,833
Industrial
i322,808
i315,337
i863,987
i889,716
Retail
i54,033
i50,088
i136,127
i147,135
Total
$
i807,357
$
i753,866
$
i2,147,192
$
i2,164,684
The
payment terms in the Company’s contracts with customers do not exceed one year and therefore contracts do not contain a significant financing component. In most cases, after appropriate credit evaluations, payments are due in arrears and are recognized as receivables. Unbilled revenue is recorded when performance obligations have been satisfied, but not yet billed to the customer. Unbilled revenue as of September 30, 2020 and December 31, 2019 was $i29.4
million and $i17.4 million respectively, and is included within accounts receivable. Deferred revenue and customer prepayments are recorded when cash payments are received or due in advance of the performance obligation being satisfied. Deferred revenue primarily includes prepaid service contracts, as well as deferred installation.
Changes in the components of deferred revenue and customer prepayments during the nine month periods
ending September 30, 2020 and 2019:
i
2020
2019
Beginning
balances as of January 1
$
i122,489
$
i105,381
Customer
pre-payments/deferred revenue
i435,952
i466,617
Revenue
recognized
(i409,391)
(i442,904)
Foreign
currency translation
i1,426
(i2,169)
Ending
balance as of September 30
$
i150,476
$
i126,925
/
The
Company generally expenses sales commissions when incurred because the amortization period is one year or less. These costs are recorded within selling, general, and administrative expenses. The Company has not disclosed the value of unsatisfied performance obligations other than customer prepayments and deferred revenue above as most contracts have an expected length of one year or less and amounts greater than one year are immaterial.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
4. iFINANCIAL INSTRUMENTS
The
Company has limited involvement with derivative financial instruments and does not use them for trading purposes. The Company enters into certain interest rate and cross currency swap agreements in order to manage its exposure to changes in interest rates. The amount of the Company's fixed obligation interest payments may change based upon the expiration dates of its interest rate and cross currency swap agreements and the level and composition of its debt. The Company also enters into certain foreign currency forward contracts to limit the
Company's exposure to currency fluctuations on the respective hedged items. For additional disclosures on derivative instruments regarding balance sheet location, fair value, and the amounts reclassified into other comprehensive income and the effective portion of the cash flow hedges, also see Note 5 and Note 9 to the interim consolidated financial statements. As also mentioned in Note 7, the Company has designated its euro-denominated debt as a hedge of a portion of its net investment in euro-denominated foreign subsidiary.
Cash Flow Hedges
In June 2019, the Company entered into a cross currency swap arrangement designated as a cash flow hedge. The agreement converts $i50
million of borrowings under the Company's credit facility into synthetic Swiss franc debt, which allows the Company to effectively change the floating rate LIBOR-based interest payments, excluding the credit spread to a fixed Swiss franc income of i0.82%. The swap matures in June 2023.
In June 2019, the Company
entered into a cross currency swap arrangement designated as a cash flow hedge. The agreement converts $i50 million of borrowings under the Company's credit facility into synthetic Swiss franc debt, which allows the Company to effectively change the floating rate LIBOR-based interest payments, excluding the credit spread to a fixed Swiss franc income of i0.95%.
The swap matures in June 2021.
In February 2019, the Company entered into a cross currency swap arrangement designated as a cash flow hedge. The agreement converts $i50 million of borrowings under the Company's credit facility into synthetic Swiss franc debt, which allows the
Company to effectively change the floating rate LIBOR-based interest payments, excluding the credit spread to a fixed Swiss franc income of i0.78%. The swap matures in June 2021.
In 2015, the Company entered into an interest rate swap agreement designated as a cash flow hedge. The agreement has the effect of changing the floating rate LIBOR-based interest payments associated with $i100
million of borrowings under the Company's credit agreement to a fixed obligation of i2.25% beginning in February 2017 and matures in February 2022.
In 2013, the Company entered into an interest rate swap agreement designated as a cash flow hedge. The agreement has the effect of changing the floating rate LIBOR-based interest payments associated with $i50
million of borrowings under the Company’s credit facility to a fixed obligation of i2.52% beginning in October 2015 and matured in October 2020.
The Company's cash flow hedges are recorded gross at fair value in the consolidated balance sheet at September 30, 2020 and December 31, 2019, respectively.
A derivative loss of $i0.5 million based upon interest rates and foreign currency rates at September 30, 2020, is expected to be reclassified from other comprehensive income (loss) to earnings in the next twelve months. The cash flow hedges remain effective as of September 30, 2020.
Other Derivatives
The
Company enters into foreign currency forward contracts in order to economically hedge short-term trade and non-trade intercompany balances largely denominated in Swiss franc, other major
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
European currencies, and the Chinese Renminbi with its foreign businesses. In accordance
with U.S. GAAP, these contracts are considered “derivatives not designated as hedging instruments.” Gains or losses on these instruments are reported in current earnings. The foreign currency forward contracts are recorded at fair value in the consolidated balance sheet at September 30, 2020 and December 31, 2019, respectively, and disclosed in Note 5. The Company recognized in other charges (income) related to these instruments, a net gain of $i7.1
million and a net loss of $i3.7 million during the three months ended September 30, 2020 and 2019, respectively, and a net gain of $i0.1
million and a net loss of $i8.2 million during the nine months ended September 30, 2020 and 2019, respectively. The gains and losses are primarily offset by the underlying transaction gains and losses on the related intercompany balances. At September 30, 2020 and December 31,
2019, these contracts had a notional value of $i500.7 million and $i494.6 million, respectively.
5. iFAIR
VALUE MEASUREMENTS
At September 30, 2020 and December 31, 2019, the Company had derivative assets totaling $i5.2 million and $i1.6
million respectively, and derivative liabilities totaling $i18.7 million and $i9.0 million, respectively. The Company
has limited involvement with derivative financial instruments and therefore does not need to present all the required disclosures in tabular format. The fair values of the interest rate swap agreements, the cross-currency swap agreements and foreign currency forward contracts that economically hedge short-term intercompany balances are estimated based upon inputs from current valuation information obtained from dealer quotes and priced with observable market assumptions and appropriate valuation adjustments for credit risk. The Company has evaluated the valuation methodologies used to develop the fair values by dealers in order to determine whether such valuations are representative of an exit price in the Company’s
principal market. In addition, the Company uses an internally developed model to perform testing on the valuations received from brokers. The Company has also considered both its own credit risk and counterparty credit risk in determining fair value and determined these adjustments were insignificant at September 30, 2020 and December 31, 2019.
Under U.S. GAAP, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement consists of observable and unobservable inputs that reflect the assumptions that a market
participant would use in pricing an asset or liability.
A fair value hierarchy has been established that categorizes these inputs into three levels:
Level 1: Quoted prices in active markets for identical assets and liabilities
Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities
NOTES TO
THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
The following table presents the Company's assets and liabilities, which are all categorized as Level 2, that are measured at fair value on a recurring basis.
Foreign currency forward contracts not designated as hedging instruments
$
i5,167
$
i1,568
Other
current assets and prepaid expenses
Total derivative assets
$
i5,167
$
i1,568
Foreign
currency forward contracts not designated as hedging instruments
$
i2,740
$
i2,392
Accrued
and other liabilities
Cash Flow Hedges:
Interest rate swap agreements
i99
i371
Accrued
and other liabilities
Cross currency swap agreement
i8,742
i—
Accrued
and other liabilities
Interest rate swap agreements
i3,075
i1,548
Other
non-current liabilities
Cross currency swap agreement
i4,091
i4,706
Other
non-current liabilities
Total derivative liabilities
$
i18,747
$
i9,017
/
The
Company had $i18.9 million and $i8.2 million of cash equivalents at September 30, 2020 and December 31,
2019, respectively, the fair value of which is determined using Level 2 inputs, through quoted and corroborated prices in active markets. The fair value of cash equivalents approximates cost.
The fair value of the Company's debt exceeds the carrying value by approximately $i52.2 million as of September 30, 2020. The fair value of the
Company's fixed interest rate debt was estimated using Level 2 inputs, primarily discounted cash flow models, based on estimated current rates offered for similar debt under current market conditions for the Company.
6. iINCOME TAXES
The
Company's reported tax rate was i21.4% and i23.6% during the three months ended September 30, 2020
and 2019, respectively and i19.4% and i18.2% during the nine months ended September 30,
2020 and 2019, respectively. The provision for taxes is based upon using the Company's projected annual effective tax rate of i20.5% and i20.0%
before non-recurring discrete tax items during 2020 and 2019, respectively. The difference between the Company's projected annual effective tax rate and the reported tax rate is primarily related to the timing of excess tax benefits associated with stock option exercises.
4.24%
$125 million ten-year Senior Notes due June 25, 2025
i125,000
i—
i125,000
3.91%
$75 million ten-year Senior Notes due June 25, 2029
i75,000
i—
i75,000
3.19%
$50 million fifteen-year Senior Notes due January 24, 2035
i50,000
i—
i50,000
1.47%
Euro 125 million fifteen-year Senior Notes due June 17, 2030
i—
i145,637
i145,637
1.30%
Euro 135 million fifteen-year Senior Notes due November 6, 2034
i—
i157,288
i157,288
Debt
issuance costs, net
(i1,191)
(i889)
(i2,080)
Total
Senior Notes
i473,809
i302,036
i775,845
$1.1
billion Credit Agreement, interest at LIBOR plus 87.5 basis points
i321,005
i71,024
i392,029
Other
local arrangements
i1,581
i54,792
i56,373
Total
debt
i796,395
i427,852
i1,224,247
Less:
current portion
(i374)
(i54,737)
(i55,111)
Total
long-term debt
$
i796,021
$
i373,115
$
i1,169,136
As
of September 30, 2020, the Company had $i700.7 million of additional borrowings available under its Credit Agreement, and the Company maintained $i153.7
million of cash and cash equivalents.
On January 24, 2020, the Company issued $50 million Senior notes with a fixed interest rate of 3.19%, which will mature January 24, 2035. The terms of the Senior Notes are consistent with the previously issued Senior Notes as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2019. The Company used the proceeds from the sale of the notes to refinance existing indebtedness and for other general corporate purposes. The
Company was in compliance with its debt covenants at September 30, 2020.
The Company has designated the EUR 125 million i1.47% Senior Notes and the EUR 135 million 1.30% Senior Notes as a hedge of a portion of its net investment in euro-denominated foreign subsidiaries to reduce foreign currency
risk associated with the net investment. Changes in the carrying value of this debt resulting from fluctuations in the euro to U.S. dollar exchange rate are recorded as foreign currency translation adjustments within other comprehensive income (loss). The Company recorded in other comprehensive income (loss) related to this net investment hedge an unrealized loss of $i11.2 million and
an unrealized gain of $i5.3 million for the three months ended September 30, 2020 and 2019, respectively, and an unrealized loss of $i11.3
million and an unrealized gain of $i6.3 million for the nine month periods ended September 30, 2020 and 2019, respectively. The Company has a loss of $i12.8
million recorded in accumulated other comprehensive income (loss) as of September 30, 2020.
Other Local Arrangements
In April 2018, two of the Company's non-U.S. pension plans issued loans totaling $i39.6 million (Swiss franc i38
million) to a wholly owned subsidiary of the Company. The loans have the same terms and conditions, which include an interest rate of Swiss franc LIBOR plus 87.5 basis points. The loans were renewed for one year in April 2020.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
8. iSHARE
REPURCHASE PROGRAM AND TREASURY STOCK
In November 2020, the Company's Board of Directors authorized an additional $i2.5 billion to be added to its share repurchase program, which has $i0.9
billion of remaining availability as of September 30, 2020. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and cash balances. Repurchases will be made through open market transactions, and the amount and timing of purchases will depend on business and market conditions, the stock price, trading restrictions, the level of acquisition activity and other factors.
The Company has purchased i29.1
million shares since the inception of the program in 2004 through September 30, 2020. During the nine months ended September 30, 2020 and 2019, the Company spent $i400 million and $i558.7
million on the repurchase of i475,530 shares and i794,603 shares at an average price per share of $i841.14
and $i703.16, respectively. The Company also reissued i144,776
shares and i226,841 shares held in treasury upon the exercise of stock options and vesting of restricted stock units during the nine months ended September 30, 2020 and 2019, respectively.
9. iACCUMULATED
OTHER COMPREHENSIVE INCOME
Comprehensive income (loss), net of tax consisted of the following as of September 30:
Three Months Ended
Nine Months Ended
2020
2019
2020
2019
Net
earnings
$
i161,767
$
i129,395
$
i386,444
$
i368,360
Other
comprehensive income (loss), net of tax
i18,332
(i13,553)
(i3,600)
(i12,572)
Comprehensive
income, net of tax
$
i180,099
$
i115,842
$
i382,844
$
i355,788
iThe
following table presents changes in accumulated other comprehensive income by component for the nine months ended September 30, 2020 and 2019:
Currency Translation Adjustment, Net of Tax
Net Unrealized Gain
(Loss) on Cash Flow Hedging Arrangements, Net of Tax
Pension and Post-Retirement Benefit Related Items, Net of Tax
iThe
following table presents amounts recognized from accumulated other comprehensive income (loss) for the three and nine month periods ended September 30:
Effective portion of (gains) / losses on cash flow hedging arrangements:
Interest rate swap agreements
$
i833
$
i31
Interest
expense
Cross currency swap agreement
i2,936
(i3,621)
(a)
Total
before taxes
i3,769
(i3,590)
Provision
for taxes
i440
(i275)
Provision
for taxes
Total, net of taxes
$
i3,329
$
(i3,315)
Recognition
of defined benefit pension and post-retirement items:
Recognition of actuarial losses and prior service cost, before taxes
$
i4,746
$
i3,890
(b)
Provision
for taxes
i1,047
i874
Provision
for taxes
Total, net of taxes
$
i3,699
$
i3,016
(a)
The cross currency swap reflects an unrealized loss of $i3.4 million for the three months ended September 30, 2020 recorded in other charges (income) that was offset by the underlying unrealized gain on the hedged debt. The cross currency swap also reflects a realized gain of $i0.4
million recorded in interest expense for the three months ended September 30, 2020.
(b) These accumulated other comprehensive income (loss) components are included in the computation of net periodic pension and post-retirement cost. See Note 11 for additional details for the three months ended September 30, 2020 and 2019.
Effective portion of (gains) / losses on cash flow hedging arrangements:
Interest rate swap agreements
$
i1,774
$
(i82)
Interest
expense
Cross currency swap agreement
i4,555
(i3,823)
(a)
Total
before taxes
i6,329
(i3,905)
Provision
for taxes
i805
(i319)
Provision
for taxes
Total, net of taxes
$
i5,524
$
(i3,586)
Recognition
of defined benefit pension and post-retirement items:
Recognition of actuarial losses and prior service cost, before taxes
$
i13,835
$
i11,639
(b)
Provision
for taxes
i3,037
i2,618
Provision
for taxes
Total, net of taxes
$
i10,798
$
i9,021
(a)
The cross currency swap reflects an unrealized loss of $i6.5 million for the nine months ended September 30, 2020 recorded in other charges (income) that was offset by the underlying unrealized gain on the hedged debt. The cross currency swap also reflects a realized gain of $i1.9
million recorded in interest expense for the three months ended September 30, 2020.
(b) These accumulated other comprehensive income (loss) components are included in the computation of net periodic pension and post-retirement cost. See Note 11 for additional details for the nine months ended September 30, 2020 and 2019i.
10. iEARNINGS
PER COMMON SHARE
In accordance with the treasury stock method, the Company has included the following common equivalent shares in the calculation of diluted weighted average number of common shares outstanding for the three and nine months ended September 30, relating to outstanding stock options and restricted stock units:
2020
2019
Three
months ended
i302,932
i392,911
Nine
months ended
i309,044
i425,627
For
the three months ended September 30, 2020, there were ino anti-dilutive outstanding options or restricted stock units. Outstanding options and restricted stock units to purchase or receive i55,568
shares of common stock for the three months ended September 30, 2019, have been excluded from the calculation of diluted weighted average number of common and common equivalent shares as such options and restricted stock units would be anti-dilutive. Options and restricted stock units to purchase or receive i56,371 and i64,649
for the nine month period ended September 30, 2020 and 2019, respectively, have been excluded from the calculation of diluted weighted average of common and common equivalent shares as such options and restricted stock units would be anti-dilutive.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands,
except share data, unless otherwise stated)
11. iNET PERIODIC PENSION COST
i
Net
periodic pension cost for the Company’s defined benefit pension plans and U.S. post-retirement medical plan includes the following components for the three months ended September 30:
U.S.
Pension Benefits
Non-U.S. Pension Benefits
Other U.S. Post-retirement Benefits
Total
2020
2019
2020
2019
2020
2019
2020
2019
Service
cost, net
$
i326
$
i266
$
i4,750
$
i3,788
$
i—
$
i—
$
i5,076
$
i4,054
Interest
cost on projected benefit obligations
i889
i1,146
i1,208
i2,547
i5
i16
i2,102
i3,709
Expected
return on plan assets
(i1,523)
(i1,472)
(i8,426)
(i7,342)
i—
i—
(i9,949)
(i8,814)
Recognition
of prior service cost
i—
i—
(i1,819)
(i1,679)
(i18)
i—
(i1,837)
(i1,679)
Recognition
of actuarial losses/(gains)
i643
i593
i5,947
i5,149
(i7)
(i173)
i6,583
i5,569
Net
periodic pension cost/(credit)
$
i335
$
i533
$
i1,660
$
i2,463
$
(i20)
$
(i157)
$
i1,975
$
i2,839
Net
periodic pension cost for the Company’s defined benefit pension plans and U.S. post-retirement medical plan includes the following components for the nine months ended September 30:
U.S.
Pension Benefits
Non-U.S. Pension Benefits
Other U.S. Post-retirement Benefits
Total
2020
2019
2020
2019
2020
2019
2020
2019
Service
cost, net
$
i978
$
i797
$
i13,795
$
i11,290
$
i—
$
i—
$
i14,773
$
i12,087
Interest
cost on projected benefit obligations
i2,667
i3,438
i3,541
i7,595
i19
i48
i6,227
i11,081
Expected
return on plan assets
(i4,571)
(i4,415)
(i24,530)
(i21,846)
i—
i—
(i29,101)
(i26,261)
Recognition
of prior service cost
i—
i—
(i5,279)
(i5,033)
(i56)
i—
(i5,335)
(i5,033)
Recognition
of actuarial losses/(gains)
i1,933
i1,780
i17,258
i15,410
(i21)
(i518)
i19,170
i16,672
Net
periodic pension cost/(credit)
$
i1,007
$
i1,600
$
i4,785
$
i7,416
$
(i58)
$
(i470)
$
i5,734
$
i8,546
/
As
previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, the Company expects to make employer contributions of approximately $i25.6 million to its non-U.S. pension plans during the year ended December
31, 2020. This estimate may change based upon several factors, including fluctuations in currency exchange rates, actual returns on plan assets and changes in legal requirements.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except share data, unless otherwise stated)
12. iRESTRUCTURING
CHARGES
For the three and nine months ended September 30, 2020, the Company has incurred $i4.6 million and $i7.3
million of restructuring expenses, respectively, which primarily relates to employee related costs. Liabilities related to restructuring activities are included in accrued and other liabilities in the consolidated balance sheet. iA rollforward of the Company’s accrual for restructuring activities for the nine months ended September 30, 2020 is as follows:
Other charges (income), net includes non-service pension costs (benefits), (gains) losses from foreign currency transactions and related hedging activities, interest income and other items. Non-service pension benefits for the three months ended September 30, 2020 and 2019 were $i3.1 million and $i1.2
million, respectively and $i9.0 million and $i3.5 million for the nine months ended September 30, 2020
and 2019, respectively.
14. SEGMENT REPORTING
As disclosed in Note 19 to the Company's consolidated financial statements for the year ended December 31, 2019, the Company has determined there are five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other.
The Company evaluates segment performance based
on Segment Profit (gross profit less research and development and selling, general and administrative expenses, before amortization, interest expense, restructuring charges, other charges (income), net and taxes).
i
The following tables show the operations of the Company’s operating segments:
(a)Other
includes reporting units in Eastern Europe, Latin America, Southeast Asia and other countries.
(b)Eliminations and Corporate includes the elimination of inter-segment transactions and certain corporate expenses and intercompany investments, which are not included in the Company’s operating segments.
(a)Other
includes reporting units in Eastern Europe, Latin America, Southeast Asia and other countries.
(b)Eliminations and Corporate includes the elimination of inter-segment transactions and certain corporate expenses and intercompany investments, which are not included in the Company’s operating segments.
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(In thousands, except
share data, unless otherwise stated)
iA reconciliation of earnings before taxes to segment profit for the three and nine month periods ended September 30 follows:
Three
Months Ended
Nine Months Ended
2020
2019
2020
2019
Earnings before taxes
$
i205,809
$
i169,359
$
i479,563
$
i450,251
Amortization
i14,121
i12,329
i42,008
i36,877
Interest
expense
i9,310
i9,800
i29,111
i27,776
Restructuring
charges
i4,570
i6,732
i7,335
i11,146
Other
charges (income), net
(i3,832)
(i2,005)
(i10,118)
(i4,253)
Segment
profit
$
i229,978
$
i196,215
$
i547,899
$
i521,797
During
the three months ended September 30, 2020, restructuring charges of $i4.6 million were recognized, of which $i2.3 million, $i0.1
million, $i1.8 million, and $i0.4 million related to the Company’s U.S., Swiss, Western European, Chinese
and Other Operations, respectively. Restructuring charges of $i6.7 million were recognized during the three months ended September 30, 2019, of which $i2.0
million, $i2.9 million, $i1.7 million, and $i0.1
million, related to the Company’s U.S., Swiss, Western European, and Chinese Operations, respectively. Restructuring charges of $i7.3 million were recognized during the nine months ended September 30, 2020, of which $i2.9
million, $i0.8 million, $i2.9 million, $i0.1
million and $i0.6 million related to the Company’s U.S., Swiss, Western European, Chinese and Other Operations, respectively. Restructuring charges of $i11.1
million were recognized during the nine months ended September 30, 2019, of which $i3.6 million, $i3.2 million, $i3.8
million, and $i0.5 million and related to the Company’s U.S., Swiss, Western European, and Chinese Operations, respectively.
15. iCONTINGENCIES
The
Company is party to various legal proceedings, including certain environmental matters, incidental to the normal course of business. Management does not expect that any of such proceedings, either individually or in the aggregate, will have a material adverse effect on the Company’s financial condition, results of operations or cash flows.
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations
The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements included herein.
General
Our interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full year ending December 31, 2020.
Changes in local currency exclude the effect of currency exchange rate fluctuations. Local currency amounts are determined by translating current and previous year consolidated financial information at an index
utilizing historical currency exchange rates. We believe local currency information provides a helpful assessment of business performance and a useful measure of results between periods. We do not, nor do we suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. We present non-GAAP financial measures in reporting our financial results to provide investors with an additional analytical tool to evaluate our operating results.
We also include in the discussion below disclosures of immaterial qualitative factors that are not quantified. Although the impact of such factors is not considered material, we believe these disclosures can be useful in evaluating our operating results.
COVID-19
The 2019 Coronavirus (COVID-19) pandemic
has resulted in millions of confirmed cases throughout the world and in all countries where we conduct business. The outbreak has caused many governments to implement stay-at-home orders, quarantines and significant restrictions on travel. Several governments have also implemented work restrictions that prohibit many employees from going to their customary work locations and which require these employees to work remotely if possible. The quarantines, travel bans, work and other restrictions were initially put in place on a national level in China in January 2020, and with the global spread of the virus, subsequently adopted in other countries and regions during the first quarter of 2020 with many restrictions commencing in Asia Pacific, Europe, North America, and South America. These restrictions continue to change as COVID-19 evolves in each country and region.
The health and safety of our employees and business partners
has been our highest priority throughout the COVID-19 pandemic, and we have implemented several preventative and protective measures relating to social distancing, hygiene, health monitoring, personal protective equipment, split shifts and remote work. We have also implemented business continuity plans and have been able to continue to support our customers with their essential businesses such as in life sciences, food manufacturing, chemicals (e.g. sanitizers, disinfectants, soaps etc.), food retail and transportation and logistics. Our production and logistics facilities are currently operational, and our office-based employees have been able to work remotely in adherence to applicable jurisdictional stay-at-home orders. Our supply chain is currently continuing with minimal interruption, and we generally maintain adequate product inventory levels and safety stock for certain components. We quickly adapted to leverage our digital and remote sales and service capabilities,
while also meeting delivery requirements with our global supply chain. Our service organization also continues to provide on-site and remote customer support to facilitate uptime, productivity and regulatory compliance.
We have also implemented various temporary cost containment measures related to workforce management and discretionary spending. Our workforce management measures
primarily include reduced work hours, salary freezes, and voluntary senior leadership salary reductions.
We maintain adequate liquidity consisting of approximately $700.7 million of additional
borrowings available under our Credit Agreement, and $153.7 million of cash and cash equivalents as of September 30, 2020.
As further described in the Risk Factors section of this Form 10-Q, COVID-19 presents several risks to our business. For example, businesses can be shutdown, supply chains can be interrupted, slowed, or rendered inoperable, and individuals can become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. COVID-19 also interferes with general commercial activity related to our supply chain and customer base. In addition, it is expected that COVID-19 will negatively affect the global economy and our customers' businesses, which will likely result in delayed or reduced purchases from us. Some customers may also have difficulty meeting their payment obligations to us, resulting in late payments or an
inability of some customers to make payments at all.
During the nine months ended September 30, 2020, COVID-19 had a negative impact on our business, primarily related to reduced customer demand in all regions. We remain cautious as uncertainties related to COVID-19 and the resulting impact to the economy continues in most regions of the world and market conditions may also change quickly. With the global spread of the virus and related negative impact to the global economy, we may experience reduced global sales volume due to lower customer demand in future quarters. The longer-term effects on our business will be impacted by the global economy and any recession implications in different regions of the world. While it is extremely difficult to estimate the extent and duration of any COVID-19 implications, the effects on our business, results of operations and financial condition
could be material.
Results of Operations – Consolidated
The following tables set forth certain items from our interim consolidated statements of operations for the three and nine month periods ended September 30, 2020 and 2019 (amounts in thousands).
Net sales were $807.4 million and $753.9 million for the three months ended September 30, 2020, and 2019, respectively, and $2.1 billion and $2.2 billion for the nine months ended September 30, 2020 and 2019, respectively. This represents an increase of 7% and a decrease of 1% in U.S. dollars for the three and nine months ended September 30, 2020, respectively. Excluding the effect of currency exchange rate fluctuations, or in local currencies, net sales increased 6% and
were flat for the three and nine months ended September 30, 2020, respectively. Net sales for the nine months ended September 30, 2020 were negatively impacted by the COVID-19 pandemic and related reduction in global customer demand on our operations. Net sales for the three months ended September 30, 2020 reflected improved customer demand in most businesses and regions with particularly strong growth in China and our laboratory-related products. While we saw increased business activity during the third quarter of 2020, we remain cautious as uncertainties relating to COVID-19 and the global economy continue and market conditions may change quickly. Net sales in local currencies may be adversely affected in future quarters by the COVID-19 pandemic related
to unfavorable economic conditions and reduced customer demand.
Net sales by geographic destination for the three months ended September 30, 2020 in U.S. dollars increased in the Americas 2%, in Europe 9% and in Asia/Rest of World 11%, and in local currencies increased in the Americas 3%, in Europe 4% and in Asia/Rest of World 10%. Our net sales by geographic destination for the nine months ended September 30, 2020 in U.S. dollars decreased in both the Americas and in Europe 1%, while Asia/Rest of World was flat. Net sales by geographic destination for the nine months ended September 30, 2020 in local currencies decreased in the Americas 1%, in Europe 2% and increased in Asia/Rest of World 1%. Net sales in Asia/Rest of World in local currency for the three months ended September
30, 2020 includes local currency growth in China of 17% that benefited from increased customer demand. A discussion of sales by operating segment is included below.
As described in Note 19 to our consolidated financial statements for the year ended December 31, 2019, our net sales comprise product sales of precision instruments and related services. Service revenues are primarily derived from repair and other services, including regulatory compliance qualification, calibration, certification, preventative maintenance and spare parts.
Net sales of products increased 7% in U.S. dollars and 6% in local currencies for the three months ended September 30, 2020 and decreased 1% in both U.S. dollars and in local currencies for the nine months ended September 30,
2020, compared to the corresponding periods in 2019. Service revenue (including spare parts) increased by 6% in U.S. dollars and 4% in local currencies for the three months ended September 30, 2020 and increased 1% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019.
Net sales of our laboratory products and services, which represented approximately 54% of our total net sales, increased 11% in U.S. dollars and 9% in local currencies for the three months ended September 30, 2020, and increased 2% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020. The local currency increase in net sales of our laboratory-related
products for the three months ended September 30, 2020 includes growth in most product categories, with excellent results in pipettes, as well as strong growth in automated chemistry and process analytics. The local currency increase in net sales of our laboratory-related products for the nine months ended September 30, 2020 includes strong growth in pipettes, automated chemistry and process analytics, offset in part by declines in other product categories.
Net sales of our industrial products and services, which represented approximately 40% of our total net sales increased, 2% in U.S. dollars and 1% in local currencies for the three months ended September 30, 2020, and decreased 3% in U.S. dollars and 2% in local currencies for the nine months ended September 30,
2020. The local currency increase in net sales of our industrial-related products for the three months ended September 30, 2020 includes strong growth in core industrial products, offset in part by a decline in product inspection. Core industrial growth included particularly strong growth in China. The local currency decrease in net sales of our industrial-related products for the nine months ended September 30, 2020 includes a decline in product inspection, offset in part by modest growth in core industrial products.
Net sales in our food retailing products and services, which represented approximately 6% of our total net sales, increased 8% in U.S. dollars and 5% in local currencies for the three months ended September 30, 2020, and decreased 7% in both U.S. dollars and
in local currencies for the nine months ended September 30, 2020. The local currency increase in food retailing for the three
months ended September 30, 2020 is primarily due to improved project activity in Europe and the Americas. The decline in food retailing for the nine months ended September 30, 2020 is primarily due to challenging market conditions.
Gross profit
Gross profit as a percentage of net sales was 58.2%
and 57.7% for the three months ended September 30, 2020 and 2019, respectively and 57.8% and 57.4% for the nine months ended September 30, 2020 and 2019, respectively.
Gross profit as a percentage of net sales for products was 59.7% and 60.2% for the three months ended September 30, 2020 and 2019, respectively, and 60.0% for both the nine months ended September 30, 2020 and 2019.
Gross profit as a percentage of net sales for services (including spare parts) was 52.7% and 48.9% for the
three months ended September 30, 2020 and 2019, respectively, and 50.5% and 48.5% for the nine months ended September 30, 2020 and 2019, respectively.
The increase in gross profit as a percentage of net sales for the three and nine months ended September 30, 2020 primarily reflects favorable price realization, benefits from temporary cost savings measures and material cost reductions, offset in part by higher transportation costs and unfavorable business mix. Gross profit for the three month period also benefited from improved sales volume.
Research and development and selling, general and administrative expenses
Research
and development expenses as a percentage of net sales was 4.3% and 4.8% for the three months ended September 30, 2020 and 2019, respectively, and was 4.7% and 5.0% for the nine months ended September 30, 2020 and 2019, respectively. Research and development expenses decreased 4% in U.S. dollars and 7% in local currencies for the three months ended September 30, 2020, and decreased 8% in U.S. dollars and 9% in local currencies for the nine months ended September 30, 2020, respectively, compared to the corresponding periods in 2019. The decrease relates to the timing of project activity and benefits from our temporary cost savings measures.
Selling,
general and administrative expenses as a percentage of net sales were 25.4% and 26.9% for the three months ended September 30, 2020 and 2019, and was 27.7% and 28.3% for the nine months ended September 30, 2020 and 2019, respectively. Selling, general and administrative expenses increased 1% in U.S. dollars and decreased 1% in local currencies for the three months ended September 30, 2020, and decreased 3% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020. The local currency decrease includes benefits from our temporary and ongoing cost savings initiatives.
Amortization, interest expense,
other charges (income), net and taxes
Amortization expense was $14.1 million and $12.3 million for the three months ended September 30, 2020 and 2019, respectively, and $42.0 million and $36.9 million for the nine months ended September 30, 2020 and 2019, respectively.
Interest expense was $9.3 million and $9.8 million for the three months ended September 30, 2020 and 2019, respectively, and $29.1 million and $27.8 million for the nine months ended September 30, 2020 and 2019, respectively.
Other charges (income), net includes non-service pension costs (benefits), (gains) losses from foreign currency transactions and hedging activities, interest income and other items. Non-service pension benefits was $3.1 million and $1.2 million for the three months ended September 30, 2020 and 2019, respectively, and $9.0 million and $3.5 million and for the nine months ended September 30, 2020 and 2019, respectively.
Our
reported tax rate was 21.4% and 23.6% during the three months ended September 30, 2020 and 2019, respectively, and 19.4% and 18.2% during the nine months ended September 30, 2020 and 2019, respectively. The provision for taxes is based upon using our projected annual effective tax rate of 20.5% and 20% before non-recurring discrete tax items for the three and nine months ended September 30, 2020 and 2019, respectively. The difference between our projected annual effective tax rate and the reported tax rate is related to the timing of excess tax benefits associated with stock option exercises.
Results of Operations – by Operating Segment
The
following is a discussion of the financial results of our operating segments. We currently have five reportable segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other. A more detailed description of these segments is outlined in Note 19 to our consolidated financial statements for the year ended December 31, 2019.
Total
net sales and net sales to external customers both increased 4% for the three months ended September 30, 2020 compared with the corresponding period in 2019. Total net sales and net sales to external customers were both flat for the nine months ended September 30, 2020 compared with the corresponding period in 2019. Net sales to external customers for the three months ended September 30, 2020 includes particularly strong growth in pipettes, as well as automated chemistry and process analytics, offset in part by a decline in product inspection. Net sales to external customers for the nine months ended September 30, 2020 includes strong growth in pipettes, transportation and logistics, and automated chemistry, offset by declines in most product categories reflecting reduced
customer demand as a result of COVID-19.
Segment profit increased $10.9 million and $16.4 million for the three and nine months ended September 30, 2020, respectively, compared to the corresponding periods in 2019. Segment profit during the three and nine months ended September 30, 2020 includes benefits from our temporary cost savings measures and margin expansion initiatives. Segment profit during the three months ended September 30, 2020 also includes benefits from our increased net sales volume.
1)Represents
U.S. dollar growth (decline) for net sales and segment profit.
Total net sales increased 6% in U.S. dollars and were flat in local currency for the three months ended September 30, 2020, and were flat in U.S. dollars and decreased 5% in local currency for the nine months ended September 30, 2020 compared to the corresponding periods in 2019. Net sales to external customers increased 16% in U.S. dollars and 11% in local currency for the three months ended September 30, 2020 and increased 1% in U.S. dollars and decreased 2% in local currency for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. The increase in local currency net sales to external customers
for the three months ended
September 30, 2020 includes strong growth in laboratory-related products, especially process analytics, pipettes and automated chemistry. Net sales to external customers for the nine months ended September 30, 2020 includes declines in most products related to lower customer demand as a result of COVID-19, offset in part by strong growth in automated chemistry, product inspection and pipettes.
Segment profit increased $7.7 million for both the three and nine month periods ended September 30,
2020, compared to the corresponding periods in 2019. Segment profit during the nine months ended September 30, 2020 includes benefits from our temporary cost savings measures and the timing of research and development activity, offset in part by unfavorable currency translation. Segment profit during the three months ended September 30, 2020 also includes benefits from our increased sales volume.
Western European Operations (amounts in thousands)
1)Represents
U.S. dollar growth (decline) for net sales and segment profit.
Total net sales increased 4% in U.S. dollars and decreased 1% in local currencies for the three months ended September 30, 2020 and decreased 3% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Net sales to external customers increased 5% in U.S. dollars and were flat in local currencies for the three months ended September 30, 2020, and decreased 4% in both U.S. dollars and in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Net sales to external customers for the three months
ended September 30, 2020 includes strong growth in laboratory-related products, especially pipettes, and food retail, offset in part by a decline in product inspection. Net sales to external customers for the nine months ended September 30, 2020 includes declines in most product categories related to lower customer demand as a result of COVID-19, offset in part by strong growth in pipettes.
Segment profit increased $7.1 million and $13.6 million for the three and nine month periods ended September 30, 2020, respectively, compared to the corresponding periods in 2019. Segment profit increased during the three and nine months ended September 30, 2020 primarily due to benefits from our temporary
cost savings measures and margin expansion initiatives and timing of research and development project activity. Segment profit for the three months ended September 30, 2020 also includes benefits from our increased net sales volume.
1)Represents
U.S. dollar growth for net sales and segment profit.
Total net sales increased 8% in U.S. dollars and 7% in local currency for the three months ended September 30, 2020 and decreased 3% in U.S. dollars and 1% in local currency for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Net sales to external customers increased 16% in U.S. dollars and 15% in local currency by origin for the three months ended September 30, 2020 and increased 2% in U.S. dollars and 3% in local currency during the nine months ended September 30, 2020, compared to the corresponding periods in 2019.
The increase in local currency net sales to external customers during the three months ended September 30, 2020 reflects strong growth in industrial and laboratory-related products that benefited from improved customer demand. However, uncertainty remains and market conditions may change quickly.
Segment profit increased $8.3 million and decreased $7.2 million for the three and nine month periods ended September 30, 2020, respectively, compared to the corresponding periods in 2019. The decrease in segment profit for the nine months ended September
30, 2020 primarily reflects the decline in total net sales as well as unfavorable foreign currency translation, offset in part by our temporary cost savings measures. Segment profit for the three months ended September 30, 2020 also includes benefits from our increased net sales volume.
1)Represents
U.S. dollar growth for net sales and segment profit.
Total net sales and net sales to external customers increased 4% in U.S. dollars and 5% in local currencies for the three months ended September 30, 2020, compared to corresponding periods in 2019. Total net sales decreased 1% in U.S. dollars and were flat in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. Net sales to external customers decreased 1% in U.S. dollars and increased 1% in local currencies for the nine months ended September 30, 2020, compared to the corresponding periods in 2019. The increase in net sales to external customers for the three months ended September 30,
2020 includes solid growth in most product categories. The increase in net sales to external customers for the nine months ended September 30, 2020 includes growth in laboratory-related products offset in part by a decline in industrial-related products due to reduced customer demand related to COVID-19.
Segment profit increased $5.6 million and $2.3 million for the three and nine months ended September 30, 2020, respectively, compared to the corresponding periods in 2019. The increase in segment profit for the nine months ended September 30, 2020 primarily reflects benefits from our temporary cost saving measures, offset in part by unfavorable foreign currency translation. The increase in segment profit for the three months ended September
30, 2020 also includes benefits from our higher net sales volume.
Liquidity and Capital Resources
Liquidity is our ability to generate sufficient cash to meet our obligations and commitments. Sources of liquidity includes, cash flows from operating activities, available borrowings under our Credit Agreement, the ability to obtain appropriate financing and our cash and cash equivalent balances. Currently, our financing requirements are primarily driven by working capital requirements, capital expenditures, share repurchases and acquisitions.
Cash provided by operating activities totaled $473.8 million during the nine months ended September 30, 2020, compared to $401.7 million in the corresponding period in 2019. The increase for the nine months ended September
30, 2020 benefited from favorable working capital including strong cash collections and higher net earnings as compared to the prior year period.
Capital expenditures are made primarily for investments in information systems and technology, machinery, equipment and the purchase and expansion of facilities. Our capital expenditures totaled $57.4 million for the nine months ended September 30, 2020 compared to $71.6 million in the corresponding period in 2019. We expect to make net investments in new or expanded manufacturing facilities of $10 million to $15 million over the next two years.
4.24% $125 million ten-year Senior Notes due June 25, 2025
125,000
—
125,000
3.91% $75 million ten-year Senior Notes due June
25, 2029
75,000
—
75,000
3.19% $50 million fifteen-year Senior Notes due January 24, 2035
50,000
—
50,000
1.47% Euro 125 million fifteen-year Senior Notes due June 17, 2030
—
145,637
145,637
1.30%
Euro 135 million fifteen-year Senior Notes due November 6, 2034
—
157,288
157,288
Debt issuance costs, net
(1,191)
(889)
(2,080)
Total Senior Notes
473,809
302,036
775,845
$1.1
billion Credit Agreement, interest at LIBOR plus 87.5 basis points
321,005
71,024
392,029
Other local arrangements
1,581
54,792
56,373
Total debt
796,395
427,852
1,224,247
Less:
current portion
(374)
(54,737)
(55,111)
Total long-term debt
$
796,021
$
373,115
$
1,169,136
As of September 30, 2020, approximately $700.7 million of additional
borrowings was available under our Credit Agreement, and we maintained $153.7 million of cash and cash equivalents. Changes in exchange rates between the currencies in which we generate cash flows and the currencies in which our borrowings are denominated affect our liquidity. In addition, because we borrow in a variety of currencies, our debt balances fluctuate due to changes in exchange rates. Further, we do not have any downgrade triggers related to ratings from rating agencies that would accelerate the maturity dates of our debt. We were in compliance with our debt covenants at September 30, 2020.
We currently believe that cash flow from operating activities, together with liquidity available under our Credit Agreement and local working capital facilities and our cash balances, will be sufficient to fund currently anticipated working capital needs and capital spending
requirements for the foreseeable future.
We continue to explore potential acquisitions. In connection with any acquisition, we may incur additional indebtedness. During the nine months ended September 30, 2019, we paid $10 million related to the settlement of the Biotix acquisition contingent consideration as further described in Note 4 of our Annual Report on Form 10-K for the year ended December 31, 2019.
In April 2018, two of our non-U.S. pension plans issued loans totaling $39.6 million (Swiss franc 38 million) to a wholly owned subsidiary of the Company. The loans have the same terms and conditions which include an interest rate of Swiss franc LIBOR plus 87.5 basis points. The loans were
renewed for one year in April 2020.
Share Repurchase Program
In November 2020, the Company's Board of Directors authorized an additional $2.5 billion to be added to our share repurchase program, which has $0.9 billion of remaining availability as of September 30, 2020. The share repurchases are expected to be funded from cash generated from operating activities, borrowings, and existing cash balances. Repurchases will be made through open market transactions, and the amount and timing of purchases will depend on business and
market conditions, stock price, trading restrictions, the level of acquisition activity, and other factors.
We have purchased 29.1 million shares since the inception of the program through September 30, 2020. During the nine months ended September 30, 2020 and 2019, we spent $400 million and $558.7 million on the repurchase of 475,530 and 794,603 shares at an average price per share of $841.14 and $703.16, respectively. We also reissued 144,776 shares and 226,841 shares held in treasury upon the exercise of stock options and vesting of restricted stock units during the nine months ended September 30, 2020 and 2019,
respectively.
Effect of Currency on Results of Operations
Our earnings are affected by changes in exchange rates. We are most sensitive to changes in the exchange rates between the Swiss franc, euro, Chinese renminbi, and U.S. dollar. We have more Swiss franc expenses than we do Swiss franc sales because we develop and manufacture products in Switzerland that we sell globally, and have a number of corporate functions located in Switzerland. When the Swiss franc strengthens against our other trading currencies, particularly the U.S. dollar and euro, our earnings decrease. We also have significantly more sales in the euro than we do expenses. When the euro weakens against the U.S. dollar and Swiss franc, our earnings also decrease. We estimate a 1% strengthening
of the Swiss franc against the euro would reduce our earnings before tax by approximately $1.6 million to $1.8 million annually.
We also conduct business in many geographies throughout the world, including Asia Pacific, the United Kingdom, Eastern Europe, Latin America, and Canada. Fluctuations in these currency exchange rates against the U.S. dollar can also affect our operating results. The most significant of these currency exposures is the Chinese renminbi. The impact on our earnings before tax of the Chinese renminbi weakening 1% against the U.S. dollar is a reduction of approximately $1.8 million to $2.0 million annually.
In addition to the effects of exchange rate movements on operating profits, our debt levels can fluctuate due to changes in exchange rates, particularly between the U.S. dollar and the Swiss franc. Based on
our outstanding debt at September 30, 2020, we estimate that a 5% weakening of the U.S. dollar against the currencies in which our debt is denominated would result in an increase of approximately $22.6 million in the reported U.S. dollar value of our debt.
You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected
in forward-looking statements because of various risks and uncertainties, including statements about expected revenue growth and long-term impacts of the COVID-19 pandemic. In some cases, you can identify forward-looking statements by terminology such as “may,”“will,”“could,”“would,”“should,”“expect,”“plan,”“anticipate,”“intend,”“believe,”“estimate,”“predict,”“potential” or “continue.”
We make forward-looking statements about future events or our future financial performance, including earnings and sales growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, customer demand, our competitive position, pricing, our supply chain, adequacy of our facilities, access to and the costs of raw materials, shipping
and supplier costs, gross margins, planned research and development efforts and product introductions, capital expenditures, cash flow, tax-related matters, the impact of foreign currencies, compliance with laws, effects of acquisitions, and the impact of the COVID-19 pandemic on our businesses.
Our forward-looking statements may not be accurate or complete, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements, including the uncertain duration and severity of the COVID-19 pandemic. See in particular “Factors Affecting Our Future Operating Results” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December
31, 2019 and other reports filed with the SEC from time to time.
Item 3.Quantitative and Qualitative Disclosures About Market Risk
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer, have concluded that these disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting during the quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
For the three and nine
months ended September 30, 2020 there were no material changes from risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, except the following update.
The COVID-19 outbreak has and will likely continue to negatively affect various aspects of our business, including our workforce and supply chain, and make it more difficult and expensive to meet our obligations to our customers, and has and will likely continue to result in reduced demand from our customers as their businesses may also be negatively affected.
Our global operations are susceptible to global
events that could have an adverse effect on our business results and financial condition.
For instance, we are susceptible to a widespread outbreak of an illness or other health issue, such as the ongoing 2019 Coronavirus outbreak ("COVID-19"), and which now has since spread globally, resulting in millions of confirmed cases throughout the world and in all countries where we conduct business. The outbreak has caused many governments to implement stay-at-home orders, quarantines and significant restrictions on travel. Several governments have also implemented work restrictions that prohibit many employees from going to their customary work locations and which require these employees to work remotely if possible. The quarantines, travel bans, work and other restrictions were initially put in place on a national level in China in January 2020, and with the
global spread of the virus, subsequently adopted in many other countries and regions throughout the first half of 2020 with many restrictions commencing in Asia Pacific, Europe, North America and South America. These restrictions continue to change as COVID-19 evolves in each country and region.
As a result of pandemic outbreaks, including COVID-19, businesses can be shut down, supply chains can be interrupted, slowed, or rendered inoperable, and individuals can become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. COVID-19 interferes with general commercial activity related to our supply chain and customer base. In addition, it is expected that COVID-19 will negatively affect the global economy and our customers' businesses, which will result in delayed or reduced purchases from us. Some customers
may also have difficulty meeting their payment obligations to us, resulting in late payments or an inability of some customers to make payments at all.
During the nine months ended September 30, 2020, COVID-19 had a negative impact on our business, primarily related to reduced global customer demand. We remain cautious as uncertainties related to COVID-19 and the resulting impact to the economy continues in all regions of the world and market conditions may also change quickly. With the global spread of the virus and related negative impact to the global economy, we may experience reduced global sales volume from lower customer demand in future quarters. Our operations could be negatively affected further if our employees who are currently not subject to stay-at-home or work restriction orders are quarantined or become ill as a result
of exposure to COVID-19, or if they become subject to governmental COVID-19 curfews or stay-at-home orders. The longer-term effects on our business will be impacted by the global economy and any recession implications in different regions of the world. While it is extremely difficult to estimate the extent and duration of any COVID-19 implications, the effects on our business, results of operations and financial condition could be material.
In
November 2020, the Company's Board of Directors authorized an additional $2.5 billion to be added to our share repurchase program, which has $0.9 billion of remaining availability as of September 30, 2020. We have purchased 29.1 million shares since the inception of the program through September 30, 2020.
During the nine months ended September 30, 2020 and 2019, we spent $400 million and $558.7 million on the repurchase of 475,530 and 794,603 shares at an average price per share of $841.14 and $703.16, respectively. We also reissued 144,776 shares and 226,841 shares held in treasury upon the exercise of
stock options and vesting of restricted stock units during the nine months ended September 30, 2020 and 2019, respectively.
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.